EDGAR Filing Documents for 0001062993-17-001280

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0001062993-17-001280

Filing Date

2017-03-10

Accepted

2017-03-10 07:27:29

Documents

Period of Report

2016-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 20-F	form20f.htm	20-F	1380017
2	EXHIBIT 4.7	exhibit4-7.htm	EX-4.7	35531
3	EXHIBIT 12.1	exhibit12-1.htm	EX-12.1	7018
4	EXHIBIT 12.2	exhibit12-2.htm	EX-12.2	6977
5	EXHIBIT 13.1	exhibit13-1.htm	EX-13.1	2664
6	EXHIBIT 13.2	exhibit13-2.htm	EX-13.2	2622
7	EXHIBIT 15.1	exhibit15-1.htm	EX-15.1	1438
8	EXHIBIT 15.2	exhibit15-2.htm	EX-15.2	35859
9	GRAPHIC	form20fx22x1.jpg	GRAPHIC	26496
10	GRAPHIC	form20fx23x1.jpg	GRAPHIC	33569
11	GRAPHIC	exhibit99-1x1x1.jpg	GRAPHIC	4582
12	GRAPHIC	financialsx1x1.jpg	GRAPHIC	6269
	Complete submission text file	0001062993-17-001280.txt		1571366

Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9

Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627

Trillium Therapeutics Inc. (Filer) CIK: 0001616212 (see all company filings)